Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Ensayo internacional pediátrico en tumor hepático

Contact
  • Protocol code: RG_15-114
  • EudraCT code: 2016-002828-85
  • Pathology: Hepatoblastoma y carcinoma hepatocelular
  • Pharmac: C5VD, SIOPEL-3 high risk, cisplatin monotherapy, GEMOX
  • Promoter: University of Birmingham
  • Principal investigator:  Sábado Álvarez, Constantino
  • Research group:  Càncer i malalties hematològiques infantils
  • Service: Oncohematologia Pediàtrica
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Finalizado

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Segundo estudio internacional intergrupo para el linfoma de Hodgkin clásico en niños y adolescentes. Estudio EuroNet-PHL-C2.

Contact
  • Protocol code: EURONET-PHL-C2
  • EudraCT code: 2012-004053-88
  • Pathology: Linfoma de Hodgkin
  • Pharmac: DECOPDAC-21 protocol +/- radiation
  • Promoter: Justus Liebig University of Giessen
  • Principal investigator:  Sábado Álvarez, Constantino
  • Research group:  Càncer i malalties hematològiques infantils
  • Service: Oncohematologia Pediàtrica
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Cerrado

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio prospectivo internacional de meduloblastoma riesgo estándar clínico en niños mayores de 3 a 5 años, con perfil bajo de riesgo biológico (PNET 5 MB - LR) o perfil medio de riesgo biológico (PNET 5 - SR MB).Estudio SIOP

Contact
  • Protocol code: SIOP-PNET5MB
  • EudraCT code: 2011-004868-30
  • Pathology: Medulloblastoma
  • Pharmac: neuraxis irradiation + chemotherapy
  • Promoter: Sociedad Española de Hematología y Oncología Pediátricas
  • Principal investigator:  Llort Sales, Anna
  • Research group:  Càncer i malalties hematològiques infantils
  • Service: Oncohematologia Pediàtrica
  • Phase: Fase III
  • Recruiting: Open
  • Status: Activo

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio aleatorizado de fase IIb con bevacizumab asociado a temozolomida ± irinotecán en niños y jóvenes con neuroblastoma resistente o recidivan.

Contact
  • Protocol code: RG_11-087
  • EudraCT code: 2012-000072-42
  • Pathology: Neuroblastoma
  • Pharmac:  bevacizumab added to temozolomide ± irinotecan
  • Promoter: The University of Birmingham
  • Principal investigator:  Moreno Martín-Retortillo, Lucas
  • Research group:  Càncer i malalties hematològiques infantils
  • Service: Oncohematologia Pediàtrica
  • Phase: Fase II
  • Recruiting: Closed
  • Status: Finalizado

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
19/06/2026

Jornada Estimulació Cerebral Profunda en nens amb Trastorns del Moviment
Ubicació
Boardroom of the VHIR Edifici Central (Floor 0)
Etiqueta
Jornades
26/03/2026

The HOPe-volution: expandint les fronteres de la perfusió hipotèrmica oxigenada
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Jornades
18/03/2026

XI Jornada de Nutrició Clínica Vall d’Hebron
Ubicació
Sala d’actes de la planta 1 del Pavelló Docent
Etiqueta
Jornades
11/03/2026

The Omics Revolution: NGS for a Data-Driven Future
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Jornades
05/03/2026

Presentació de la 7a edició del Mocador Solidari de Vall d'Hebron
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Jornades
14/05/2026

Career Day 2026
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Jornades
Subscribe to